

[Ho

using Unit Front Cover Flap]

((POMALYST REMS® logo))

POMALYST Risk Evaluation and Mitigation Strategy (REMS) program education and prescribing safety kit

[Housing Unit Front Cover]

Risks of POMALYST® (pomalidomide)

- POMALYST is similar to the medicine thalidomide (THALOMID®). Thalidomide can cause severe life-threatening birth defects. If POMALYST is used during pregnancy, it can cause birth defects or embryo-fetal death. POMALYST must not be used by pregnant females and females who are able to get pregnant. Females who are able to get pregnant must avoid pregnancy while taking POMALYST
- Blood clots in your arteries (heart attacks and strokes), veins (deep vein thrombosis) and lungs (pulmonary embolism) can happen if you take POMALYST

POMALYST, in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.


((POMALYST logo))

APPEARS THIS WAY ON ORIGINAL

[Housing Unit Spine]

POMALYST Risk Evaluation and Mitigation Strategy (REMS) program education and prescribing safety kit

APPEARS THIS WAY ON ORIGINAL



[Housing Unit Back Cover]

((POMALYST REMS® logo))

Prescriber quick reference guide

1. The prescriber provides comprehensive counseling.
2. The prescriber verifies negative pregnancy test for all female patients of reproductive potential.
3. The prescriber completes POMALYST® (pomalidomide) Patient-Physician Agreement Form with each patient and sends to Celgene.
4. Female patients complete initial mandatory confidential survey by:
 - Visiting **www.CelgeneRiskManagement.com**
 - Accessing the Celgene REMS mobile app
 - Calling Celgene Customer Care Center at **1-888-423-5436**

Male patients do not need to complete the initial survey.

All patients must complete subsequent mandatory confidential surveys as outlined in the Prescriber Guide to POMALYST REMS® Program.

5. The prescriber completes mandatory confidential survey and receives authorization number by:
 - Visiting **www.CelgeneRiskManagement.com**
 - Accessing the Celgene REMS mobile app
 - Calling Celgene Customer Care Center at **1-888-423-5436**
6. The prescriber writes POMALYST prescription and includes authorization number and patient risk category.
7. The prescriber sends prescription to certified pharmacy.

This flow sheet should be used only as a quick reference and only after reviewing all of the POMALYST REMS® procedures.

POMALYST is only available under a restricted distribution program, POMALYST REMS®.

Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS, enclosed.

((Celgene logo)) ((POMALYST REMS® logo)) ((POMALYST logo))

POMALYST® is a registered trademark of Celgene Corporation. POMALYST REMS® is a trademark of Celgene Corporation.

© 2016 Celgene Corporation 6/16 REMS-POM16744

APPEARS THIS WAY ON ORIGINAL

